Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Netflix (NFLX) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Jan. 20, 2026 at 4:45 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Netflix will add 2+ live operation centers in 2026 in UK and Asia

    80% confidence
  • Q2 2024 operating margin expanded 5 percentage points year-over-year

    80% confidence
  • Approximately one-third of Netflix members have access to TV-based games through client upgrades

    80% confidence
  • Netflix targets 2026 operating margin of 31.5%, up 2 percentage points including 0.5 point M&A expense headwind

    80% confidence
  • Ad-supported ARM is currently below ad-free ARM, representing a monetization gap

    80% confidence
  • Netflix 2025 operating margin reached 26%, raised from 25% guidance

    80% confidence
  • 2026 operating margin will be 2.5 points higher excluding M&A expenses

    80% confidence
  • Netflix has less than 10% of TV time in all major markets

    80% confidence
  • Netflix executed 200+ live events

    80% confidence
  • Netflix will spend $17 billion on content cash in 2026, growing slower than revenue

    80% confidence
  • Netflix operating profit grew approximately 30% in 2025

    80% confidence
  • Netflix expects approximately $6 billion in free cash flow for 2026

    80% confidence
  • Japanese consumers watch 50-67% less TV than US consumers

    80% confidence
  • The Warner Bros. deal is pro-consumer, pro-innovation, pro-worker, pro-creator, and pro-growth

    80% confidence
  • Post-launch party pack games (Boggle, Pictionary, LEGO) achieved approximately 10% reach into eligible members

    80% confidence
  • Netflix retention is among the best in the industry

    80% confidence
  • Netflix targets $3 billion in ad revenue for 2026, doubling from 2025

    80% confidence
  • Netflix revenue grew 16% annually in 2025

    80% confidence
  • Netflix operates in 12 ad markets

    80% confidence
  • Netflix primary quality metric reached all-time high in 2025

    80% confidence
  • There are 500+ million smart TV households globally that are non-Netflix members

    80% confidence
  • Q2 2024 revenue growth was 17% reported

    80% confidence
  • Gaming market size is approximately $140 billion in consumer spend excluding China

    80% confidence
  • The Warner Bros. acquisition represents a tremendous, very achievable opportunity

    80% confidence
  • Netflix tested vertical video for approximately 6 months

    80% confidence
  • Live events represent a relatively small portion of total view hours

    80% confidence
  • Modular interactive video ads with dynamic templates completed testing in late 2025 with global rollout in 2026

    80% confidence
  • Post-acquisition, 85% of Netflix revenue will come from current core businesses

    80% confidence
  • India ranked #2 and #3 for Netflix paid net adds and revenue growth in Q2 2024

    80% confidence
  • Warner Bros. global box office exceeds $4 billion

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript — Source | Via News | ViaNews EU